Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide As Highly Sensitive and Specific OATP1B1 Biomarkers

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2020 Sep 22

PMID 32961594

Citations 16

Authors

Mikko Neuvonen

Paivi Hirvensalo

Aleksi Tornio

Brian Rago

Mark West

Sarah Lazzaro

Sumathy Mathialagan

Manthena Varma

Matthew A Cerny

Chester Costales

Ragu Ramanathan

A David Rodrigues

Mikko Niemi

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the sensitivity and specificity of endogenous glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides (GCDCA-3G and GDCA-3G) as substrates for organic anion transporting polypeptide 1B1 (OATP1B1) in humans. We measured fasting levels of plasma GCDCA-3G and GDCA-3G using liquid chromatography-tandem mass spectrometry in 356 healthy volunteers. The mean plasma levels of both compounds were ~ 50% lower in women than in men (P = 2.25 × 10 and P = 4.73 × 10 ). In a microarray-based genome-wide association study, the SLCO1B1 rs4149056 (c.521T>C, p.Val174Ala) variation showed the strongest association with the plasma GCDCA-3G (P = 3.09 × 10 ) and GDCA-3G (P = 1.60 × 10 ) concentrations. The mean plasma concentration of GCDCA-3G was 9.2-fold (P = 8.77 × 10 ) and that of GDCA-3G was 6.4-fold (P = 2.45x10 ) higher in individuals with the SLCO1B1 c.521C/C genotype than in those with the c.521T/T genotype. No other variants showed independent genome-wide significant associations with GCDCA-3G or GDCA-3G. GCDCA-3G was highly efficacious in detecting the SLCO1B1 c.521C/C genotype with an area under the receiver operating characteristic curve of 0.996 (P < 0.0001). The sensitivity (98-99%) and specificity (100%) peaked at a cutoff value of 180 ng/mL for men and 90 ng/mL for women. In a haplotype-based analysis, SLCO1B1*5 and *15 were associated with reduced, and SLCO1B1*1B, *14, and *35 with increased OATP1B1 function. In vitro, both GCDCA-3G and GDCA-3G showed at least 6 times higher uptake by OATP1B1 than OATP1B3 or OATP2B1. These data indicate that the hepatic uptake of GCDCA-3G and GDCA-3G is predominantly mediated by OATP1B1. GCDCA-3G, in particular, is a highly sensitive and specific OATP1B1 biomarker in humans.

Citing Articles

Ultra-Sensitive Quantification of Coproporphyrin-I and -III in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry.

Negami J, Suzuki Y, Sato H, Toyama D, Tanaka R, Ono H ACS Omega. 2024; 9(47):47135-47144.

PMID: 39619527 PMC: 11603277. DOI: 10.1021/acsomega.4c07566.

Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon.

Arya V, Ma J, Kvitne K Pharmaceutics. 2024; 16(7).

PMID: 39065552 PMC: 11280074. DOI: 10.3390/pharmaceutics16070855.

Comprehensive Clinical and Genetic Analyses of Circulating Bile Acids and Their Associations With Diabetes and Its Indices.

Choucair I, Mallela D, Hilser J, Hartiala J, Nemet I, Gogonea V Diabetes. 2024; 73(8):1215-1228.

PMID: 38701355 PMC: 11262044. DOI: 10.2337/db23-0676.

Non-targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function.

Hamalainen K, Hirvensalo P, Neuvonen M, Tornio A, Backman J, Lehtonen M Clin Transl Sci. 2024; 17(3):e13773.

PMID: 38515340 PMC: 10958181. DOI: 10.1111/cts.13773.

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity.

Kiiski J, Neuvonen M, Kurkela M, Hirvensalo P, Hamalainen K, Tarkiainen E Hum Genomics. 2024; 18(1):11.

PMID: 38303026 PMC: 10835938. DOI: 10.1186/s40246-024-00579-8.

References

Chu X, Liao M, Shen H, Yoshida K, Zur A, Arya V . Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clin Pharmacol Ther. 2018; 104(5):836-864. DOI: 10.1002/cpt.1216. View

Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K . Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. Pharm Res. 2017; 34(8):1601-1614. DOI: 10.1007/s11095-017-2184-5. View

Ho R, Choi L, Lee W, Mayo G, Schwarz U, Tirona R . Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007; 17(8):647-56. PMC: 4063287. DOI: 10.1097/FPC.0b013e3280ef698f. View

Gessner A, Konig J, Fromm M . Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther. 2019; 105(6):1386-1394. DOI: 10.1002/cpt.1360. View

Konig J, Cui Y, Nies A, Keppler D . A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000; 278(1):G156-64. DOI: 10.1152/ajpgi.2000.278.1.G156. View

Konig J, Cui Y, Nies A, Keppler D . Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000; 275(30):23161-8. DOI: 10.1074/jbc.M001448200. View

Frommherz L, Bub A, Hummel E, Rist M, Roth A, Watzl B . Age-Related Changes of Plasma Bile Acid Concentrations in Healthy Adults--Results from the Cross-Sectional KarMeN Study. PLoS One. 2016; 11(4):e0153959. PMC: 4836658. DOI: 10.1371/journal.pone.0153959. View

Nies A, Niemi M, Burk O, Winter S, Zanger U, Stieger B . Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013; 5(1):1. PMC: 3706890. DOI: 10.1186/gm405. View

Galman C, Angelin B, Rudling M . Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med. 2011; 270(6):580-8. DOI: 10.1111/j.1365-2796.2011.02466.x. View

10.

Pasanen M, FREDRIKSON H, Neuvonen P, Niemi M . Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82(6):726-33. DOI: 10.1038/sj.clpt.6100220. View

11.

Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S . Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet. 2018; 34(1):78-86. DOI: 10.1016/j.dmpk.2018.09.003. View

12.

Giacomini K, Balimane P, Cho S, Eadon M, Edeki T, Hillgren K . International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013; 94(1):23-6. DOI: 10.1038/clpt.2013.12. View

13.

Xiang X, Backman J, Neuvonen P, Niemi M . Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. Basic Clin Pharmacol Toxicol. 2011; 110(3):245-52. DOI: 10.1111/j.1742-7843.2011.00792.x. View

14.

Stephens M, Donnelly P . A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003; 73(5):1162-9. PMC: 1180495. DOI: 10.1086/379378. View

15.

Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T . Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6):554-65. DOI: 10.1016/S0009-9236(03)00060-2. View

16.

Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R . Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs. Clin Pharmacol Ther. 2019; 107(4):1004-1013. PMC: 7158214. DOI: 10.1002/cpt.1695. View

17.

Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T . Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004; 75(5):415-21. DOI: 10.1016/j.clpt.2003.12.016. View

18.

Shen H, Chen W, Drexler D, Mandlekar S, Holenarsipur V, Shields E . Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metab Dispos. 2017; 45(8):908-919. DOI: 10.1124/dmd.117.075531. View

19.

Stephens M, Smith N, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68(4):978-89. PMC: 1275651. DOI: 10.1086/319501. View

20.

Chu X, Shih S, Shaw R, Hentze H, Chan G, Owens K . Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab Dispos. 2015; 43(6):851-63. DOI: 10.1124/dmd.115.063347. View